# Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects

> **NCT07150975** · PHASE3 · RECRUITING · sponsor: **Gan & Lee Pharmaceuticals.** · enrollment: 420 (estimated)

## Conditions studied

- Obesity/Overweight in Adult

## Interventions

- **DRUG:** GZR18
- **DRUG:** Semaglutide(Wegovy® )

## Key facts

- **NCT ID:** NCT07150975
- **Lead sponsor:** Gan & Lee Pharmaceuticals.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-23
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 420 (ESTIMATED)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07150975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07150975, "Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07150975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*